Published weekly, SciBX provides concise analysis of the scientific contentand commercial potential of the most important translational research withthe potential to transform human therapeutics and diagnostics. Bydistilling the flood of life sciences literature down to the 25 keyscientific developments each week and providing in-depth analysis of themost important findings, SciBX provides a unique scientific and commercialperspective on today's breakthrough science. The same content will bepublished weekly in both formats.

The HTML version is expected to appeal to librarians serving academic andcorporate research institutions.

Peter Collins, Publishing Director at Nature Publishing Group, said: "Thisis a valuable development for SciBX. SciBX is now compatible with the sitelicense subscription model that many of our customers are familiar with,whilst maintaining the simplicity and convenience of PDF delivery forbiotechnology and pharmaceutical executives and the investment community."

Under the site license option, SciBX will be integrated with the serviceson www.nature.com, allowing full-text search of archived content,registration for Table of Contents E-alerts, links to references andinclusion of articles from SciBX in Saved Search results. The completearchive back to Issue 1 will be available in HTML by the end of the year.Pricing for site-wide access is calculated based on institution type andsize.

David Flores, Co-Founder, President and CEO of BioCentury noted that SciBXplays a key role in communicating between academic and corporatescientists: "SciBX serves academic researchers and their institutions byshowcasing the value of their intellectual property and identifying thecritical next steps that industry believes are necessary to bring theirinnovative science to the healthcare community. So, SciBX is a uniqueliterature awareness and educational tool for academic scientists. And forthe corporate R&D and business development departments, SciBX is anessential awareness and analysis tool that identifies new science withpotential commercial, competitive and investment impact."

About SciBX

SciBX: Science-Business eXchange is a joint publication from BioCenturyPublications, Inc. and Nature Publishing Group that evaluates hundreds ofhigh impact peer-reviewed scientific papers and selects the mostcommercially relevant findings that merit deeper analysis. Each issuecontains Analysis, in-depth articles examining the commercial impact andnext steps required to translate the newest developments in the lab intoinnovative healthcare solutions. This coverage is complemented by TheDistillery, a compilation of the most recently published science withcommercial implications, including information on patent and licensingstatus. SciBX is published weekly in PDF format and is e-mailed to personalsubscribers throughout the world. SciBX is also now available as afull-text, HTML web site for institutional site-wide access atwww.nature.com/scibx.

About BioCentury

BioCentury Publications, Inc., independently owned and based in RedwoodCity, Calif., provides essential biopharma intelligence from offices in theU.S. and Europe. Over nearly 16 years, a global audience of biotech andpharmaceutical executives and investors has benefited from BioCentury'sdeep knowledge, data-driven analysis, independent perspective andtrustworthy content available through the company's publications, onlinedata resources and collaborative industry conferences. Long respected forthe thought leadership provided by BioCentury, the Bernstein Report onBioBusiness®, the company also publishes BioCentury Extra, a concisedaily news report for executives, and BioCentury Part II, a complete weeklycompendium of deals, product developments and financing events. Theseauthoritative reports are backed by the BCIQ(TM) online businessintelligence platform, which provides access to information on more than4,000 public and private companies, 5,000 biopharma compounds and $200billion in financings. For more information, please visitwww.biocentury.com.

About Nature Publishing Group

Nature Publishing Group (NPG) is dedicated to serving the academic,professional scientific and medical communities. NPG's flagship title,Nature, was first published in 1869. NPG also publishes NatureBiotechnology and Nature Reviews Drug Discovery -- thepre-eminent publications for academic and corporate scientists interestedin drug discovery -- together with the Nature research journals, NatureReviews, Nature Clinical Practice and a range of prestigious academicjournals including society-owned publications. NPG also provides newscontent through Nature News and scientific career information and free jobpostings on Naturejobs. NPG is a global company with principal offices inLondon and New York and offices in Basingstoke, Boston, Buenos Aires,Delhi, Hong Kong, Madrid, Melbourne, Munich, Paris, San Francisco, Tokyoand Washington DC. For more information, please go to www.nature.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Inquiries Contact:Thomas CareyBioCentury Publications, Inc.Email Contact+1 650 595-5333BioCentury Publications, Inc.P.O. Box 1246San Carlos, CA 94070, USAwww.biocentury.comGrace BaynesNature Publishing GroupEmail Contact+44 (0)20 7014 4063Nature Publishing Group75 Varick StreetNew York, NY 10013, USAwww.nature.com